NuCana Has Been Granted European Patent Number EP3683225 Titled "NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS"
NuCana Appoints Ian Webster as Chief Financial Officer
NuCana Appoints Ian Webster CFO, Effective Immediately
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
NuCana shares are trading lower. The company reported Q4 financial results.
NuCana Q4 2025 EPS $0.00 and Revenue $0.00
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
NuCana Appoints Theresa Bruce as Chief Operating Officer
NuCana Appoints Theresa Bruce COO, Effective Jan. 1
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
Nucana Reappoints Hugh S. Griffith As CEO, Effective Dec. 15
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
NuCana Presents Data Showing Clinical Activity And Favorable Safety For NUC-7738 At ESMO Congress
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
NuCana Announces China's National Intellectual Property Administration Has Granted A Composition Of Matter Patent For NUC-7738, Its Novel Anti-Cancer Agent
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
